Rashtriya Newsflash

DelveInsight’s “Autism Spectrum Disorder Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the market dynamics, epidemiology, prescription patterns, physician perspectives, and future opportunities shaping the global Autism Spectrum Disorder therapeutics landscape.

Interested to know which Autism Spectrum Disorder therapies will capture the highest market share?

Download the report to understand the latest Autism Spectrum Disorder market trends and forecasts – https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Autism Spectrum Disorder Market Report

• The Autism Spectrum Disorder market size is expected to experience steady growth during the forecast period 2024–2034, driven by increased awareness, improved diagnostic practices, and the development of new therapies.

• The market is currently dominated by big pharmaceutical companies like Otsuka, Johnson & Johnson, and Flynn Pharma, offering approved therapies such as ABILIFY (aripiprazole), RISPERDAL (risperidone), and SLENYTO (prolonged-release melatonin).

• Companies including MapLight Therapeutics, Hoffmann-La Roche, Axial Therapeutics, and Yamo Pharmaceuticals are developing pipeline assets such as ML-004, RG7816, AB-2004, and L1-79 for Autism Spectrum Disorder.

• In Feb 2025, DeFloria, Inc. announced that the FDA completed its review of the IND application for AJA001, an orally delivered, multi-cannabinoid botanical drug for ASD symptoms, with Phase 2 trials planned to begin by mid-2025.

• In January 2025, the FDA granted Orphan Drug Designation to Capsida Biotherapeutics for CAP-002, a first-in-class gene therapy for STXBP1 disorder.

• The report covers epidemiological trends and market forecasts across the seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning 2020 to 2034.

Gain a competitive edge in the Autism Spectrum Disorder Market by exploring our in-depth analysis @ Autism Spectrum Disorder Prevalence – https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Autism Spectrum Disorder Market Overview

Autism Spectrum Disorder is a neurodevelopmental disorder characterized by difficulties with social communication and social interaction, along with restricted and repetitive patterns in behaviors, interests, and activities. Symptoms present early in development and affect daily functioning, generally falling into two categories: social communication and interaction difficulties, and restricted or repetitive behaviors.

Diagnosis is based on evaluations that often involve a team including a physician and a psychologist, and may include disciplines such as speech and language pathology or occupational therapy, with standardized observations, cognitive assessments, and interviews gathering information across multiple settings.

Currently, no treatment has been shown to cure Autism Spectrum Disorder, but interventions such as applied behavioral analysis (ABA), occupational therapy, speech therapy, physical therapy, and pharmacological therapy can reduce symptoms and improve cognitive ability and daily living skills. Current pharmacological options include aripiprazole, risperidone, and SLENYTO.

Factors Driving the Growth of the Autism Spectrum Disorder MarketRising Prevalence of Autism Spectrum Disorder (ASD)

The increasing global prevalence of Autism Spectrum Disorder is a major factor driving market growth, leading to higher demand for diagnostic services, therapies, and long-term care solutions.

Growing Awareness and Early Diagnosis

Increased awareness among parents, educators, and healthcare professionals has improved early screening and diagnosis, enabling timely intervention and expanding the patient population seeking treatment and support services.

Advancements in Therapeutic Approaches

Ongoing research into behavioral therapies, digital therapeutics, and pharmacological treatments is improving symptom management and expanding the range of available treatment options for individuals with ASD.

Government Support and Healthcare Initiatives

Various government programs and funding initiatives focused on developmental disorders are enhancing access to early intervention programs, specialized education, and healthcare services for individuals with autism.

Increasing Research and Pipeline Development

Pharmaceutical and biotechnology companies are actively investing in clinical research to develop novel therapies targeting core and associated symptoms of autism, strengthening the overall market landscape.

Autism Spectrum Disorder Market Segment Analysis

The Autism Spectrum Disorder market is segmented by therapies and by class, into current and emerging markets for the study period 2020–2034, with the market of each region further segmented by therapy to provide a detailed view of current and future market share. One of the emerging drugs anticipated to launch during the forecast period is ML-004 by MapLight Therapeutics.

Autism Spectrum Disorder Market Regional AnalysisUnited States Holds a Significant Share of the Autism Spectrum Disorder Market

• In 2022, the United States held a significant share of the overall 7MM Autism Spectrum Disorder market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

• As per analysis, about 1 in 44 children aged 8 years have been identified with Autism Spectrum Disorder in the US, with boys found to be four times more likely to be identified with ASD than girls.

• Various sources estimate that around 700,000 people in the UK have a diagnosis of autism, with 1 in 100 children in the UK having Autism Spectrum Disorder.

• In Germany, children aged 6 to 11 years showed the highest prevalence, estimated at around 6.0 per 1,000.

• In Japan, the adjusted Autism Spectrum Disorder prevalence was around 3%, with a male-to-female ratio of 2.2:1, with gender differences in symptom presentation and co-morbid intellectual disability potentially contributing to the male bias in diagnoses.

Autism Spectrum Disorder Key Companies

Autism Spectrum Disorder Companies include:

• Aardvark Therapeutics, Inc.

• Otsuka Pharmaceutical

• H. Lundbeck A/S

• Jazz Pharmaceuticals

• MapLight Therapeutics

• Vanda Pharmaceuticals

• ACADIA Pharmaceuticals Inc.

• AbbVie

• Hoffmann-La Roche

• Yamo Pharmaceuticals LLC

• Axial Therapeutics, Inc.

• And Others.

Download the report to understand which factors are driving Autism Spectrum Disorder Market Trends

Latest Highlights from the Autism Spectrum Disorder Market

• In April 2025, NeuroNOS, a subsidiary of Beyond Air, announced that the FDA granted Orphan Drug Designation to its lead investigational therapy, BA-102, for treating Phelan-McDermid Syndrome (PMS), a condition linked to Autism Spectrum Disorder, with first-in-human clinical trials for ASD planned to begin in 2026.

• In March 2025, GRIN Therapeutics, Inc. announced that the FDA granted Orphan Drug Designation for its investigational drug, radiprodil, for the treatment of GRIN-related neurodevelopmental disorder (NDD).

• In Feb 2025, DeFloria, Inc. announced that the FDA completed its review of the IND application for AJA001, an orally delivered, multi-cannabinoid botanical drug for treating symptoms of ASD, with Phase 2 trials planned to begin by mid-2025.

• In January 2025, the FDA granted Orphan Drug Designation to Capsida Biotherapeutics for CAP-002, a first-in-class gene therapy for STXBP1 disorder, developed in collaboration with Dr. Mingshan Xue at Texas Children’s Duncan Neurological Research Institute.

Discover key developments and opportunities in the Autism Spectrum Disorder Market @ Autism Spectrum Disorder Market Size

Autism Spectrum Disorder Market Outlook

There is no cure for Autism Spectrum Disorder, but various interventions and treatments have been approved for symptom management. RISPERDAL (risperidone) was the first US FDA-approved medication for symptoms associated with ASD in children and adolescents, including aggressive behavior, deliberate self-injury, and temper tantrums, approved by the FDA in October 2006 and available in oral tablet and oral solution formulations. ABILIFY (aripiprazole) is also FDA-approved for the treatment of irritability in children and adolescents with ASD. SLENYTO (melatonin), a prolonged-release melatonin minitablet available in 1 mg and 5 mg dosage forms, is the first and only pharmacotherapy approved for the treatment of insomnia in children with ASD.

Developmental approaches focus on improving specific developmental skills, such as language or physical skills, and are often combined with behavioral approaches, with speech and language therapy being the most common developmental therapy for people with ASD. Psychological approaches can also help individuals cope with anxiety, depression, and other mental health issues.

In the pipeline, ML-004 (MapLight Therapeutics) is a selective 5-HT1B receptor agonist being evaluated in a Phase II study for sociability and irritability in ASD, currently in a randomized, double-blind, placebo-controlled trial of up to 150 adults and adolescents. RG7816/RO7017773 (Hoffmann-La Roche) is a selective positive allosteric modulator of the GABAA α5 receptor, being evaluated in a Phase II study in participants aged 15–45 years with ASD. AB-2004 (Axial Therapeutics) is a gut-targeted molecular therapeutic addressing the microbiome-gut-brain axis, currently in a Phase IIb study in a 13-to-17-year-old ASD population.

According to DelveInsight, the Autism Spectrum Disorder market in the 7MM is expected to change significantly during the study period 2020–2034.

Scope of the Autism Spectrum Disorder Market Report

Study Period: 2020–2034

Forecast Period: 2024–2034

Geographies Covered: The US, EU4 (Germany, France, Italy, and Spain), UK, and Japan

Market Size (2034): USD XX Million

Major Autism Spectrum Disorder Companies: Aardvark Therapeutics, Inc., Otsuka Pharmaceutical, H. Lundbeck A/S, Jazz Pharmaceuticals, MapLight Therapeutics, Vanda Pharmaceuticals, ACADIA Pharmaceuticals Inc., AbbVie, Axial Therapeutics, Inc., Hoffmann-La Roche, Yamo Pharmaceuticals LLC, and others.

Market Segments Covered: Total Market Size, Market Size by Therapies, Market Size by Class, and Geography.

Epidemiology Segmentation: Total Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, and Total Treated Cases of Autism Spectrum Disorder in the 7MM.

Key Focus Areas: Emerging Therapies, Marketed Therapies, Diagnosis and Treatment Practices, Prescription Patterns, Physician Perspectives, and Market Accessibility.

Table of Contents

1. Key Insights

2. Report Introduction

3. Autism Spectrum Disorder (ASD) Market Overview at a Glance

4. Epidemiology and Market Methodology

5. Executive Summary

6. Autism Spectrum Disorder (ASD) Key Events

7. Disease Background and Overview: Autism Spectrum Disorder (ASD)

8. Autism Spectrum Disorder (ASD) Epidemiology and Patient Population

9. Autism Spectrum Disorder (ASD) Patient Journey

10. Autism Spectrum Disorder (ASD) Marketed Therapies

11. Autism Spectrum Disorder (ASD) Emerging Therapies

12. Autism Spectrum Disorder (ASD): Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Autism Spectrum Disorder (ASD) Unmet Needs

15. SWOT Analysis

16. Autism Spectrum Disorder (ASD) Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

How DelveInsight’s Autism Spectrum Disorder Market Report Helps CXOs and Business Leaders

• Evaluate the current and future market opportunity across the seven major markets, including the United States, EU4, UK, and Japan, through detailed epidemiology-based forecasts and patient population trend analysis.

• Benchmark leading Autism Spectrum Disorder therapies, marketed products, and pipeline assets through comprehensive company profiling and product portfolio evaluation.

• Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging market participants such as MapLight Therapeutics, Axial Therapeutics, and Yamo Pharmaceuticals, along with recent regulatory designations and clinical developments.

• Assess the impact of upcoming Orphan Drug Designations, regulatory approvals, and clinical trial results on market share, prescription patterns, and commercial success.

• Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet diagnostic needs, treatment practices, and evolving epidemiological trends within the Autism Spectrum Disorder landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Abhishek kumar
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market